Stable Isotope Labeling Kinetics (SILK) in patients with familial forms of neurodegenerative diseases.

痴呆症研究所该项目与加速药物发现和翻译优先领域保持一致，因为它将提供一种新的工具来研究抑制或改变神经退行性疾病中疾病相关蛋白表达的药物。行业合作伙伴：C2 N-该项目将采用C2 N开发的稳定同位素标记动力学（SILK）平台，其中将稳定的非放射性同位素标记的氨基酸输注到人类受试者中。稳定的同位素结合到大脑中新合成的蛋白质中，这些蛋白质将通过连续收集血浆和CSF进行采样。在第一阶段，我们将确定TDP-43，tau，-突触核蛋白和新的短A物种的生产和清除率。博士生将专注于该项目的实验室测量。

Dementia Research InstituteThe project is aligned with the Accelerating Medicines Discovery and Translation priority area as it will provide a new tool to study drugs that inhibit or modify the expression of disease-related proteins in neurodegenerative diseases. Industrial Partner: C2N - the project will employ the stable isotope labeling kinetic (SILK) platform, developed by C2N, in which a stable, non-radioactive isotope labeled amino acid is infused into human subjects. The stable isotope incorporates into newly synthesized proteins in the brain, which will be sampled through serial collection of plasma and CSF. In the first phase, we will determine production and clearance rates of TDP-43, tau, -synuclein and novel short A species. The PhD student will focus on laboratory measurements in the project.